Antiverse

Antiverse raises £3.5M ($4.6M) to advance generative AI antibody design platform

Increases total equity financing raised to £7.2M ($10.1M) New facilities in Boston and Prague will provide increased capacity to deliver pipeline of pharma and biotech projects Funding to progress internal assets targeting multiple GPCRs and Ion Channels towards clinical trials 15 October 2024 – Cardiff, Wales, – Antiverse, a techbio company designing antibodies for challenging...

Antiverse and GlobalBio, Inc extend collaboration to advance antibody cancer therapeutics

Collaboration successfully identified antibodies with therapeutic potential as checkpoint inhibitors in oncology Two antibodies showing high specificity for PD-1 are now being progressed to preclinical development Project leveraged Antiverse’s AI-driven Antibody Discovery Platform and GlobalBio’s ALTHEA semisynthetic libraries 16 October 2023 -- Cardiff, UK and Massachusetts, US -- Antiverse, a biotechnology company developing a computational...
MediCentre, Heath Park, Cardiff CF14 4UJ